Experimental modeling of ovarian carcinoma

DOI: 10.29296/2618723X-2020-03-05

Ya. Murazov, A. Nyuganen, A. Artem'yeva

N.N. Petrov National Medical Research Center of Oncology, Healthcare Ministry of Russia,

197758, Russia, St.-Petersburg, pos. Pesochniy, st. Leningradskaya 68

E-mail: [email protected]

Keywords: ovarian cancer high-grade serous ovarian carcinoma peritoneal carcinomatosis intraperitoneal therapy preclinical trials

For citation:

Murazov Yа.G., Niuganen A.O., Artemyeva A.S. Experimental modeling of ovarian carcinoma. Laboratory Animals for Science. 2020; 3. https://doi.org/10.29296/2618723X-2020-03-06


Despite the success achieved in the surgical and drug treatment of ovarian cancer, mortality among women from this malignant neoplasm remains high. Epithelial ovarian cancer (EOC) is the predominant histological type, and high-grade serous carcinoma (HGSC) is the main subtype of EOC, associated with approximately 90% of deaths. Currently, there is evidence of the dualistic origin of HGSC. Did it arise as a result of metaplastic transformation and simply morphologically resembled tumors of the oviduct (analogue of the fallopian tubes in women) or did it primarily arise from oviduct cells. Understanding the biology of tumor growth, assessing the efficacy and safety of pharmacological agents, new treatment methods (including normothermic, hyperthermic intraperitoneal chemotherapy), and studying prognostic and predictive biomarkers are impossible without reproducible experimental models in vivo that provide acceptable predictiveness of preclinical results for further clinical trials. The review presents data about the main groups of experimental models of EOC in laboratory animals. The advantages and disadvantages of spontaneous, carcinogen-induced, genetically engineered, syngeneic models are described. Transgenic models with inactivation of both p53 and Rb pathways, Brca 1/2, Pten, and Tp53 genes in the secretory epithelium of fallopian tubes (oviducts) of mice with double knockout of Dicer and Pten genes are described. Data on models based on transplantation of xenografts of human cell lines (A2780, OVCAR-3, and SKOV-3), as well as PDX (patient-derived xenograft) models in immunodeficient animals is presented. Anatomical sites of the main methods of xenograft transplantation (orthotopic and heterotopic) are considered. The morphological characteristics of the modeled malignant neoplasms are given. The metastatic potential of experimental models is described, information on the local and systemic dissemination of tumors, the formation of ascites is given. Our own results of studying high-grade syngeneic ovarian carcinoma in Wistar female rats are presented briefly. Applicable research areas are indicated for each model group. The article will be of interest to a wide range of specialists, involved in fundamental and registration preclinical studies.

Full text avaliable in Russain only


The study was performed without external funding.

Author’s сontributions

Murazov Y.G. – conception of the work, data collection and systematization, writing and editing of the manuscript

Niuganen A.O. –data collection and systematization, editing of the manuscript

Artemyeva A.S. – critical revision of the article, editing of the manuscript.


  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68 (6): 394–424. doi: 10.3322/caac.21492.
  2. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11: 287–299. Published 2019 Apr 30. doi: 10.2147/IJWH.S197604.
  3. van Baal JOAM, van Noorden CJF, Nieuwland R, Van de Vijver KK, Sturk A, van Driel WJ, Kenter GG, Lok CAR. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review. J Histochem Cytochem. 2018 Feb; 66 (2): 67-83. doi: 10.1369/0022155417742897.
  4. Helderman, R., Löke, D. R., Kok, H. P., Oei, A. L., Tanis, P. J., Franken, N., & Crezee, J. (2019). Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review. Cancers, 11 (1), 78. https: //doi.org/10.3390/cancers11010078.
  5. Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect. 1987; 73: 35-51. doi: 10.1289/ehp.877335.
  6. Kuhn E, Tisato V, Rimondi E, Secchiero P. Current Preclinical Models of Ovarian Cancer. J Carcinog Mutagen 2015, 6: 2.
  7. Cooper TK, Gabrielson KL. Spontaneous lesions in the reproductive tract and mammary gland of female non-human primates. Birth Defects Res B Dev Reprod Toxicol. 2007; 80 (2): 149-170. doi: 10.1002/bdrb.20105.
  8. Krarup T. Oocyte destruction and ovarian tumorigenesis after direct application of a chemical carcinogen (9: 0-dimethyl-1: 2-benzanthrene) to the mouse ovary. Int J Cancer. 1969; 4 (1): 61-75. doi: 10.1002/ijc.2910040109.
  9. Toth B. Susceptibility of guinea pigs to chemical carcinogens: 7,12-Dimethylbenz (a)anthracene and urethan. Cancer Res. 1970; 30 (10): 2583-2589.
  10. Tunca JC, Ertürk E, Ertürk E, Bryan GT. Chemical induction of ovarian tumors in rats. Gynecol Oncol. 1985; 21 (1): 54-64. doi: 10.1016/0090-8258 (85)90232-x.
  11. Nishida T, Sugiyama T, Katabuchi H, Yakushiji M, Kato T. Histologic origin of rat ovarian cancer induced by direct application of 7,12-dimethylbenz (a)anthracene. Nihon Sanka Fujinka Gakkai Zasshi. 1986; 38 (4): 570-574.
  12. Chuffa LG, Fioruci-Fontanelli BA, Mendes LO, Fávaro WJ, Pinheiro PF, Martinez M, Martinez FE. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. PLoS One. 2013 Dec 18; 8 (12): e81676. doi: 10.1371/journal.pone.0081676.
  13. Zhang S, Dolgalev I, Zhang T, Ran H, Levine DA, Neel BG. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun. 2019; 10 (1): 5367. Published 2019 Nov 26. doi: 10.1038/s41467-019-13116-2.
  14. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003 Mar 15; 63 (6): 1389-97.
  15. Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA. 2012; 109 (10): 3921-3926. doi: 10.1073/pnas.1117135109.
  16. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, Chen JY, Ohman AW, Stepule CD, Kwak S, Karst AM, Hirsch MS, Setlur SR, Crum CP, Dinulescu DM, Drapkin R. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca; Tp53; Pten models. Cancer Cell. 2013 Dec 9; 24 (6): 751-65. doi: 10.1016/j.ccr.2013.10.013.
  17. Sherman-Baust CA, Kuhn E, Valle BL, Shih IeM, Kurman RJ, Wang TL, Amano T, Ko MS, Miyoshi I, Araki Y, Lehrmann E, Zhang Y, Becker KG, Morin PJ. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol. 2014 Jul; 233 (3): 228-37. doi: 10.1002/path.4353.
  18. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004; 10 (6): 1032-1042. doi: 10.1016/j.ymthe.2004.08.013.
  19. Magnotti E, Marasco WA. The latest animal models of ovarian cancer for novel drug discovery. Expert Opin Drug Discov. 2018; 13 (3): 249-257. doi: 10.1080/17460441.2018.1426567.
  20. Hernandez L, Kim MK, Lyle LT, Bunch KP, House CD, Ning F, Noonan AM, Annunziata CM. Characterization of ovarian cancer cell lines as in vivo models for preclinical studies. Gynecol Oncol. 2016 Aug; 142 (2): 332-40. doi: 10.1016/j.ygyno.2016.05.028.
  21. Hallas-Potts, A., Dawson, J.C. & Herrington, C.S. Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas. Sci Rep 9, 5515 (2019). https: //doi.org/10.1038/s41598-019-41941-4.
  22. Tudrej P, Kujawa KA, Cortez AJ, Lisowska KM. Characteristics of in Vivo Model Systems for Ovarian Cancer Studies. Diagnostics (Basel). 2019; 9 (3): 120. Published 2019 Sep 14. doi: 10.3390/diagnostics9030120.
  23. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013; 4: 2126. doi: 10.1038/ncomms3126.
  24. Preston CC, Goode EL, Hartmann LC, Kalli KR, Knutson KL. Immunity and immune suppression in human ovarian cancer. Immunotherapy. 2011; 3 (4): 539-556. doi: 10.2217/imt.11.20.
  25. Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res. 1993; 13 (2): 283-286.
  26. Wu J, Zheng Y, Tian Q, Yao M, Yi X. Establishment of patient-derived xenograft model in ovarian cancer and its influence factors analysis. J Obstet Gynaecol Res. 2019; 45 (10): 2062-2073. doi: 10.1111/jog.14054.
  27. Ricci F, Bizzaro F, Cesca M, Guffanti F, Ganzinelli M, Decio A, Ghilardi C, Perego P, Fruscio R, Buda A, Milani R, Ostano P, Chiorino G, Bani MR, Damia G, Giavazzi R. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. Cancer Res. 2014 Dec 1; 74 (23): 6980-90. doi: 10.1158/0008-5472.
  28. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, Gilks CB, Wang YZ. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol. 2005 Jan; 96 (1): 48-55. doi: 10.1016/j.ygyno.2004.09.025.
  29. Butler KA, Hou X, Becker MA, Zanfagnin V, Enderica-Gonzalez S, Visscher D, Kalli KR, Tienchaianada P, Haluska P, Weroha SJ. Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. Neoplasia. 2017 Aug; 19 (8): 628-636. doi: 10.1016/j.neo.2017.04.007.
  30. Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat Genet. 2017 Nov; 49 (11): 1567-1575. doi: 10.1038/ng.3967.
  31. Scott CL, Mackay HJ, Haluska P Jr. Patient-derived xenograft models in gynecologic malignancies. Am Soc Clin Oncol Educ Book. 2014; e258-e266. doi: 10.14694/EdBook_AM.2014.34.e258.
  32. Погосянц, Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая асцитная опухоль яичника крысы (штамм ОЯ). Вопросы онкологии. 1962; 8 (11): 29-36. [Pogosyants, E.E., Prigozhina E.L., Egolina N.A. Perevivaemaya astsitnaya opukhol' yaichnika krysy (shtamm OYa). Vopr Oncol. 1962; 8 (11): 29-36, (In Russian)].
  33. Беспалов В.Г., Жабин А.А., Стуков А.Н., Беляева О.А., Муразов Я.Г., Семёнов А.Л., Коньков С.А., Крылова И.М. Синергизм противоопухолевого действия диоксадэта и цисплатина на модели асцитной опухоли яичника. Сибирский онкологический журнал. 2013; (1): 42-46. [Bespalov VG, Zhabin AA, Stukov AN, Beliaeva OA, Murazov IG, Semenov AL, Kon’kov SA, Krylova IM. Sinergizm protivoopukholevogo deistviya dioksadehta i cisplatina na modeli astsitnoi opukholi yaichnika. Siberian journal of oncology. 2013; (1): 42-46. (In Russ.)].
  34. Sekiya S, Iwasawa H, Takamizawa H. Comparison of the intraperitoneal and intravenous routes of cisplatin administration in an advanced ovarian cancer model of the rat. Am J Obstet Gynecol. 1985; 153 (1): 106-111. doi: 10.1016/0002-9378 (85)90605-2.
  35. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, Persons DL, Smith PG, Terranova PF. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000 Apr; 21 (4): 585-91. doi: 10.1093/carcin/21.4.585.
  36. Wilkinson-Ryan I, Pham MM, Sergent P, Tafe LJ, Berwin BL. A Syngeneic Mouse Model of Epithelial Ovarian Cancer Port Site Metastases. Transl Oncol. 2019 Jan; 12 (1): 62-68. doi: 10.1016/j.tranon.2018.08.020. Epub 2018 Sep 27.
  37. Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol Oncol. 2008 Feb; 108 (2): 385-94. doi: 10.1016/j.ygyno.2007.10.035.
  38. McCloskey CW, Goldberg RL, Carter LE, Gamwell LF, Al-Hujaily EM, Collins O, Macdonald EA, Garson K, Daneshmand M, Carmona E, Vanderhyden BC. A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. Front Oncol. 2014 Mar 18; 4: 53. doi: 10.3389/fonc.2014.00053.
  39. Hornung R, Major AL, McHale M, Liaw LH, Sabiniano LA, Tromberg BJ, Berns MW, Tadir Y. In vivo detection of metastatic ovarian cancer by means of 5-aminolevulinic acid-induced fluorescence in a rat model. J Am Assoc Gynecol Laparosc. 1998 May; 5 (2): 141-8. doi: 10.1016/s1074-3804 (98)80080-7.

You may be interested